Clover's RSV Vaccine Re-Vaccination Trial Shows Positive Results in Older Adults.

Clover Biopharmaceuticals announced additional positive data from a Phase I clinical trial in the US evaluating re-vaccination with its RSV PreF vaccine candidate. The results showed a trend of approximately 60-80% higher RSV neutralizing antibodies for Clover's vaccine compared to GSK's AREXVY in older adults who previously received an initial dose of AREXVY. Re-vaccination with Clover's vaccine boosted RSV nAbs to approximately 120-135% of peak levels observed after an initial dose of AREXVY. The findings strengthen the potential best-in-class profile of Clover's RSV+hMPV±PIV3 combination vaccines.